Non-Hodgkin’s lymphoma is a common form of blood cancer with a high proportion of patients either developing treatment resistance or relapsing after initial treatment. The combination of multiple therapies is commonly used to treat treatment-resistant/relapsed patients. However, response rates can be poor, necessitating the development of patient-specific approaches for therapy selection. This study led by A/Prof Edward Chow and Dr Anand Jeyasekharan, describes the application of quadratic phenotypic optimization platform (QPOP), in the context of non-Hodgkin’s lymphoma, where QPOP is a patient-specific drug testing platform that allows drug combinations to be tested and selected based on efficacy against individual patient tumour samples obtained by biopsy. In addition to demonstrating that QPOP is feasible for application in a clinical setting, QPOP-guided treatment regimens were also shown to provide benefit to treatment-resistant/relapsed patients, warranting the evaluation of this approach in future clinical trials.

Read more: https://pubmed.ncbi.nlm.nih.gov/36260690/